Article
Radiology, Nuclear Medicine & Medical Imaging
Hang Zheng, Kaiwen Liu, Yao Yang, Bo Liu, Xinya Zhao, Yong Chen, Yuemin Feng, Min Meng, Xu Tan, Qiang Zhu
Summary: Compared to RFA, MWA showed better tumor control for subcapsular HCC within the Milan criteria. There was no difference in the incidence of major complications between the two groups.
EUROPEAN RADIOLOGY
(2022)
Article
Oncology
Hidekatsu Kuroda, Tomoaki Nagasawa, Yudai Fujiwara, Hiroki Sato, Tamami Abe, Yohei Kooka, Kei Endo, Takayoshi Oikawa, Kei Sawara, Yasuhiro Takikawa
Summary: Microwave ablation using Thermosphere(TM) technology showed similar overall survival and recurrence-free survival outcomes compared to radiofrequency ablation for hepatocellular carcinoma. Despite no significant differences in survival outcomes between the two methods, microwave ablation required fewer insertions, making it a recommended treatment option for tumors larger than 2 cm.
Article
Surgery
Hong Jae Jeon, Hyuk Soo Eun, In Sun Kwon, Byung Seok Lee, Eaum Seok Lee, Woo Sun Rou, Jae Kyu Sung, Hee Seok Moon, Sun Hyung Kang, Hyun Seok Lee, Seok-Hwan Kim, Kwangsik Chun, Seok Hyun Kim
Summary: This study compared the therapeutic outcomes of laparoscopic radiofrequency ablation (LRFA) and percutaneous radiofrequency ablation (PRFA) in patients with hepatocellular carcinoma (HCC). The results revealed that LRFA was associated with longer recurrence-free survival and favorable overall survival compared to PRFA. Therefore, LRFA should be considered as the primary therapy for eligible HCC patients.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Review
Oncology
Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, Masatoshi Kudo
Summary: Thermal ablation therapy, including RFA and MWA, is a widely used treatment for hepatocellular carcinomas. It achieves good outcomes with minimal invasiveness. Successful thermal ablation therapy requires understanding the principles and characteristics of the treatment, assessing the benefits and risks, precise needle control and visualization, utilizing imaging guidance techniques, and evaluating therapeutic response. This overview provides essential information for the clinical application of thermal ablation.
Article
Radiology, Nuclear Medicine & Medical Imaging
Yi Yang, Yi Chen, Feng Ye, Xiaojing Cao, Yujing Xin, Yanan Wang, Yong Lei, Xiao Li, Duiping Feng, Xiang Zhou, Qingsheng Fan
Summary: This study aimed to identify risk factors and develop a model to predict recurrence-free survival after radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) within the Milan criteria. Results showed male gender, multiple tumors, and cirrhosis as independent risk factors for late recurrence. Late recurrence is mainly attributed to de novo HCC in the context of cirrhosis.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Qingsong Deng, Minglian He, Chunchuan Fu, Kai Feng, Kuansheng Ma, Leida Zhang
Summary: Radiofrequency ablation (RFA) is an effective treatment method for hepatocellular carcinoma (HCC), with characteristics of being minimally invasive, safe, and having good local tumor control ability. With technological advancements, RFA is playing an increasingly important role in the comprehensive treatment of HCC.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2022)
Article
Gastroenterology & Hepatology
Hideyuki Tamai, Jumpei Okamura
Summary: The study showed that the new generation microwave thermosphere ablation (MTA) could provide safer and more curative treatment for small hepatocellular carcinoma (HCC) in a shorter ablation time compared to radiofrequency ablation (RFA). The MTA group had significantly lower 3-year local tumor progression rate and total complication rate than the RFA group.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Oncology
Sooyeon Kim, Jungsue Lee, Chai Hong Rim
Summary: This meta-analysis investigates the benefits of local treatment for oligometastasis in hepatocellular carcinoma (HCC) and finds that it significantly improves survival rates and outcomes.
Article
Surgery
Tomoki Ryu, Yuko Takami, Yoshiyuki Wada, Shin Sasaki, Hajime Imamura, Hiroki Ureshino, Hideki Saitsu
Summary: This study retrospectively reviewed 81 patients with multifocal hepatocellular carcinoma who underwent combined hepatectomy and microwave ablation, finding an overall survival rate of 54% at 5 years. The major complication rate post-surgery was 10%, with certain factors like des-gamma-carboxy prothrombin level and tumor characteristics identified as independent risk factors for survival outcomes. The study concludes that the combined procedure is safe and feasible for selected patients with multifocal HCC.
ASIAN JOURNAL OF SURGERY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chao An, Wang-Zhong Li, Zhi-Mei Huang, Xiao-Ling Yu, Yu-Zhi Han, Fang-Yi Liu, Song-Song Wu, Jie Yu, Ping Liang, Jinhua Huang
Summary: In patients with small single perivascular hepatocellular carcinoma, microwave ablation exhibited better tumor control than radiofrequency ablation, with a significantly higher local tumor progression rate observed in the radiofrequency ablation group. Additionally, there was a significant interaction effect of ablation modality and type of peritumoral vessel on local tumor progression, with differences observed in periportal HCC but not perivenous HCC.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Melanie A. Kimm, Sophia Kaestle, Matthias M. R. Stechele, Elif Oecal, Lisa Richter, Muzaffer R. Uemuetlue, Regina Schinner, Osman Oecal, Lukas Salvermoser, Marianna Alunni-Fabbroni, Max Seidensticker, S. Nahum Goldberg, Jens Ricke, Moritz Wildgruber
Summary: This study found that local ablative therapies may have systemic effects on circulating immune cells in HCC patients. The levels of mMDSCs increased in almost all patients following local ablation, and there were varying alterations in monocyte subpopulations depending on the type of ablation. Liquid biopsy of circulating monocytes may provide information on the inflammatory response and immune reaction following local ablation.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Peiman Habibollahi, Rahul A. Sheth, Erik N. K. Cressman
Summary: Liver cancer is a growing global concern with limited treatment options. The most common treatment methods are ablation techniques such as radiofrequency ablation and microwave ablation. However, difficulties in completely identifying residual cancer cells remain in these procedures, highlighting the need for further advancements in treatment strategies.
Article
Gastroenterology & Hepatology
Tomoki Ryu, Yuko Takami, Yoshiyuki Wada, Hideki Saitsu
Summary: The study examined the long-term outcomes of operative microwave ablation for hepatocellular carcinoma within 3 cm and 3 nodules, revealing good overall survival rates and recurrence-free survival rates. Independent risk factors for prognosis were identified, and a prognostic staging model based on these factors was developed to predict outcomes.
JOURNAL OF GASTROINTESTINAL SURGERY
(2022)
Article
Gastroenterology & Hepatology
Masaya Sato, Makoto Moriyama, Tsuyoshi Fukumoto, Tomoharu Yamada, Taijiro Wake, Ryo Nakagomi, Takuma Nakatsuka, Tatsuya Minami, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Shuichiro Shiina, Kazuhiko Koike, Mitsuhiro Fujishiro, Ryosuke Tateishi
Summary: This study developed a transformer model to predict overall survival in HCC patients treated with RFA and compared its performance with a deep learning model. The transformer-based model showed better discrimination performance and the ability to stratify patients into different risk groups. It also provided personalized cumulative recurrence prediction for each patient.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Maria Conticchio, Riccardo Inchingolo, Antonella Delvecchio, Letizia Laera, Francesca Ratti, Maximiliano Gelli, Ferdinando Anelli, Alexis Laurent, Giulio Vitali, Paolo Magistri, Giacomo Assirati, Emanuele Felli, Taiga Wakabayashi, Patrick Pessaux, Tullio Piardi, Fabrizio di Benedetto, Nicola de'Angelis, Javier Briceno, Antonio Rampoldi, Rene Adam, Daniel Cherqui, Luca Antonio Aldrighetti, Riccardo Memeo
Summary: In elderly patients (> 70 years) with HCC in Milan criteria, surgical resection provided better long-term oncological outcomes compared to radiofrequency ablation, despite a longer length of stay and a higher rate of severe postoperative complications.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Ryo Yano, Yuki Okazaki, Koutarou Sunago, Yusuke Imai, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa
Summary: This study investigated the correlation between splenic stiffness measured using 2D shear wave elastography and hepatic venous pressure gradient (HVPG) in patients with chronic liver disease. The results showed that splenic shear wave speed (SWS) was closely correlated with HVPG and could serve as a predictive marker for high-risk varices.
HEPATOLOGY RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Korenobu Hayama, Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Motoh Iwasa, Hiroshi Hasegawa, Koichi Takaguchi, Akemi Tsutsui, Haruki Uojima, Hisashi Hidaka, Hironao Okubo, Tatsuya Suzuki, Kentaro Matsuura, Toshifumi Tada, Naoto Kawabe, Joji Tani, Asahiro Morishita, Toru Ishikawa, Yoshitaka Arase, Yoshihiro Furuichi, Keizo Kato, Kazuhito Kawata, Makoto Chuma, Akito Nozaki, Atsushi Hiraoka, Tsunamasa Watanabe, Tatehiro Kagawa, Hidenori Toyoda, Nobuhiko Taniai, Hiroshi Yoshida, Yasuhito Tanaka, Katsuhiko Iwakiri
Summary: This study aimed to evaluate the outcome in patients with portal vein thrombosis (PVT) who received antithrombin III-based therapy. The results showed that maintenance therapy, favorable response, and absence of PVT progression may suppress or control liver-related events in antithrombin III-based therapy for PVT patients.
HEPATOLOGY RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Shigeo Shimose, Rie Sugimoto, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Yuki Tanaka, Fujimasa Tada, Hideko Ohama, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Yu Noda, Naoki Kamachi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Summary: This study evaluated the therapeutic effects and safety of ramucirumab following atezolizumab plus bevacizumab treatment. The results showed increased therapeutic effect in patients with atezolizumab plus bevacizumab failure, and patients with splenomegaly and low BMI should be monitored for ascites during ramucirumab treatment.
HEPATOLOGY RESEARCH
(2023)
Article
Oncology
Takeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Satoru Kakizaki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada
Summary: This study demonstrates that the HCC-GRIm score serves as a novel prognostic score for HCC patients treated with Atez/Bev, with a high score being associated with unfavorable prognosis in terms of disease progression and overall survival.
Article
Oncology
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada
Summary: This study compared the efficacy and safety of atezolizumab and bevacizumab in patients with viral and non-viral infection in clinical settings. The results showed that there were no significant differences in the response rate, disease control rate, progression-free survival, and 12-month survival rates between viral and non-viral-related HCC patients. No significant difference in treatment-related adverse events was found between the two groups. Atez/Bev demonstrated good efficacy and safety for HCC patients with both viral and non-viral infections.
Article
Oncology
Masaki Kaibori, Kengo Yoshii, Yuzo Umeda, Takahito Yagi, Takehiro Okabayashi, Kenta Sui, Akira Mori, Yuhei Hamaguchi, Kiyoshi Kajiyama, Daisuke Hokuto, Kazuteru Monden, Tomoharu Yoshizumi, Yoriko Nomura, Kan Toriguchi, Jong Man Kim, Gi Hong Choi, Je Ho Ryu, Yangseok Koh, Koo Jeong Kang, Young Kyoung You, Kwang-Sik Chun, Young Seok Han, Chan Woo Cho, Young Il Choi, Dong-Sik Kim, Jae Do Yang, Keita Mori, Atsushi Hiraoka, Hiroki Yamaue, Masafumi Nakamura, Masakazu Yamamoto, Itaru Endo
Summary: This study compared the prognostic impact of laparoscopic left hepatectomy (LLH) with open left hepatectomy (OLH) on patient survival after resection of left hepatocellular carcinoma (HCC). The results showed that the LLH group had lower rates of postoperative complications and hepatic decompensation compared to the OLH group. Recurrence-free survival (RFS) was better in the LLH group, while overall survival (OS) did not significantly differ. Subgroup analyses showed consistent trends in favor of LLH in patients with larger tumor size or single tumors.
Article
Biochemistry & Molecular Biology
Kozue Kanemitsu-Okada, Masanori Abe, Yoshiko Nakamura, Teruki Miyake, Takao Watanabe, Osamu Yoshida, Yohei Koizumi, Masashi Hirooka, Yoshio Tokumoto, Bunzo Matsuura, Mitsuhito Koizumi, Yoichi Hiasa
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease worldwide, and therapeutic strategies targeting multidirectional pathways are necessary. Fibrosis is closely related to prognosis, and B cell-activating factor (BAFF) is associated with NAFLD severity. This study found that BAFF plays a crucial role in the development of non-alcoholic steatohepatitis (NASH) and may be a promising therapeutic target for NASH.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study compares the response rates of lenvatinib and atezolizumab plus bevacizumab in the first-line treatment of hepatocellular carcinoma (HCC) patients. The results show that lenvatinib achieves higher response rates in all patient subgroups. Patients who achieve complete response with atezolizumab plus bevacizumab can achieve a better overall survival compared to other treatments.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Hideko Ohama, Atsushi Hiraoka, Fujimasa Tada, Kanako Kato, Yoshiko Fukunishi, Emi Yanagihara, Masaya Kato, Hironobu Saneto, Hirofumi Izumoto, Hidetaro Ueki, Takeaki Yoshino, Shogo Kitahata, Tomoe Kawamura, Taira Kuroda, Yoshifumi Suga, Hideki Miyata, Jun Hanaoka, Jota Watanabe, Hiromi Ohtani, Masashi Hirooka, Masanori Abe, Bunzo Matsuura, Tomoyuki Ninomiya, Yoichi Hiasa
Summary: This study aimed to evaluate the clinical usefulness of surgical resection (SR) with or without radio frequency ablation (RFA) for intermediate-stage hepatocellular carcinoma (HCC). The results showed no significant differences in recurrence-free survival (RFS) and overall survival (OS) between the SR group and the SR plus RFA group. Both groups achieved an acceptable five-year cumulative survival rate. This retrospective study suggests that SR could be a favorable option for intermediate-stage HCC.
Article
Gastroenterology & Hepatology
Yasunori Yamamoto, Shinya Furukawa, Teruki Miyake, Junichi Watanabe, Aki Kato, Katsunori Kusumoto, Eiji Takeshita, Yoshio Ikeda, Naofumi Yamamoto, Yuka Saeki, Yoichi Hiasa
Summary: This study examined the association between exercise habits and irritable bowel syndrome (IBS) in a young Japanese population. It found that moderate frequency and intensity of exercise were both inversely related to IBS, and exercising with others also helped prevent IBS.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Hironori Ochi, Atsushi Hiraoka, Takaaki Tanaka, Toshie Mashiba, Hideko Ohama, Fujimasa Tada, Cao Fang, Toyoki Shimamoto, Michiko Amano, Nobuaki Azemoto, Masashi Hirooka, Tomoyuki Yokota, Yoichi Hiasa
Summary: This study aims to investigate the prognosis and recurrence after radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma (HCC) in different age groups. The results showed that patients aged 80 years and older had worse prognosis, but there were no significant differences in recurrence rates among the groups. For patients aged 80 years and older, in addition to the modified albumin-bilirubin index, performance status was also a significant factor affecting prognosis. Therefore, preoperative evaluation of performance status and management of other diseases could contribute to a prolonged prognosis in elderly patients with early-stage HCC.
HEPATOLOGY RESEARCH
(2023)
Article
Oncology
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Lorenza Rimassa, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: A real-world study found that adherence to the IMbrave150 trial inclusion criteria improves the safety and efficacy of atezolizumab plus bevacizumab treatment for unresectable HCC. Among patients who did not meet the IMbrave150 inclusion criteria, those with ALBI grade 1 showed a longer overall survival.
Article
Urology & Nephrology
Yasunori Yamamoto, Shinya Furukawa, Teruki Miyake, Osamu Yoshida, Kana Shiraishi, Yu Hashimoto, Kazuhiro Tange, Masakazu Hanayama, Shogo Kitahata, Tomoyuki Ninomiya, Sen Yagi, Seiyuu Suzuki, Naozumi Shibata, Hidehiro Murakami, Katsuhisa Ohashi, Hideomi Tomida, Eiji Takeshita, Yoshio Ikeda, Yoichi Hiasa
Summary: This study investigated the association between nocturia and constipation in patients with ulcerative colitis (UC). The results showed that the severity of nocturia is positively associated with constipation.